228 related articles for article (PubMed ID: 17923463)
1. Effect of valsartan compared with valsartan/hydrochlorothiazide on plasma levels of cellular adhesion molecules: the Val-MARC trial.
Conen D; Everett BM; Glynn RJ; Ridker PM
Heart; 2008 Mar; 94(3):e13. PubMed ID: 17923463
[TBL] [Abstract][Full Text] [Related]
2. Tolerability and blood pressure-lowering efficacy of the combination of amlodipine plus valsartan compared with lisinopril plus hydrochlorothiazide in adult patients with stage 2 hypertension.
Poldermans D; Glazes R; Kargiannis S; Wernsing M; Kaczor J; Chiang YT; Yen J; Gamboa R; Fomina I
Clin Ther; 2007 Feb; 29(2):279-89. PubMed ID: 17472820
[TBL] [Abstract][Full Text] [Related]
3. Effects of force-titrated valsartan/hydrochlorothiazide versus amlodipine/hydrochlorothiazide on ambulatory blood pressure in patients with stage 2 hypertension: the EVALUATE study.
Lacourcière Y; Wright JT; Samuel R; Zappe D; Purkayastha D; Black HR;
Blood Press Monit; 2009 Jun; 14(3):112-20. PubMed ID: 19384192
[TBL] [Abstract][Full Text] [Related]
4. [Lowering of blood pressure, blood pressure amplitude and heart rate by treatment with valsartan or valsartan/hydrochlorothiazide. Results of an open observation study of 11,447 hypertensives].
Weisser B; Vetter H; Mengden T
Dtsch Med Wochenschr; 2003 Mar; 128(11):541-4. PubMed ID: 12635025
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and tolerability of combination therapy with valsartan/hydrochlorothiazide in the initial treatment of severe hypertension.
Calhoun DA; Glazer RD; Pettyjohn FS; Coenen PD; Zhao Y; Grosso A
Curr Med Res Opin; 2008 Aug; 24(8):2303-11. PubMed ID: 18593517
[TBL] [Abstract][Full Text] [Related]
6. Time to achieve blood-pressure goal: influence of dose of valsartan monotherapy and valsartan and hydrochlorothiazide combination therapy.
Weir MR; Levy D; Crikelair N; Rocha R; Meng X; Glazer R
Am J Hypertens; 2007 Jul; 20(7):807-15. PubMed ID: 17586417
[TBL] [Abstract][Full Text] [Related]
7. Effects of valsartan alone versus valsartan/simvastatin combination on ambulatory blood pressure, C-reactive protein, lipoproteins, and monocyte chemoattractant protein-1 in patients with hyperlipidemia and hypertension.
Rajagopalan S; Zannad F; Radauceanu A; Glazer R; Jia Y; Prescott MF; Kariisa M; Pitt B
Am J Cardiol; 2007 Jul; 100(2):222-6. PubMed ID: 17631074
[TBL] [Abstract][Full Text] [Related]
8. Impact of supportive measures on drug adherence in patients with essential hypertension treated with valsartan: the randomized, open-label, parallel group study VALIDATE.
Düsing R; Handrock R; Klebs S; Tousset E; Vrijens B
J Hypertens; 2009 Apr; 27(4):894-901. PubMed ID: 19300114
[TBL] [Abstract][Full Text] [Related]
9. Lack of pharmacokinetic interactions of aliskiren, a novel direct renin inhibitor for the treatment of hypertension, with the antihypertensives amlodipine, valsartan, hydrochlorothiazide (HCTZ) and ramipril in healthy volunteers.
Vaidyanathan S; Valencia J; Kemp C; Zhao C; Yeh CM; Bizot MN; Denouel J; Dieterich HA; Dole WP
Int J Clin Pract; 2006 Nov; 60(11):1343-56. PubMed ID: 17073832
[TBL] [Abstract][Full Text] [Related]
10. Statins reduce oxidized low-density lipoprotein levels, but do not alter soluble intercellular cell-adhesion molecule-1 and vascular cell-adhesion molecule-1 levels in subjects with hypercholesterolaemia.
Rosenson RS; Wolff D; Tangney CC
Clin Sci (Lond); 2004 Feb; 106(2):215-7. PubMed ID: 12967321
[TBL] [Abstract][Full Text] [Related]
11. Indices of low-grade chronic inflammation in polycystic ovary syndrome and the beneficial effect of metformin.
Diamanti-Kandarakis E; Paterakis T; Alexandraki K; Piperi C; Aessopos A; Katsikis I; Katsilambros N; Kreatsas G; Panidis D
Hum Reprod; 2006 Jun; 21(6):1426-31. PubMed ID: 16497699
[TBL] [Abstract][Full Text] [Related]
12. Soluble adhesion molecules in end-stage renal disease: a predictor of outcome.
Suliman ME; Qureshi AR; Heimbürger O; Lindholm B; Stenvinkel P
Nephrol Dial Transplant; 2006 Jun; 21(6):1603-10. PubMed ID: 16476720
[TBL] [Abstract][Full Text] [Related]
13. Reaching the therapeutic goal in hypertension: results from the Canadian valsartan observational study. (Diovantage 4).
Tardif JC; Curnew GP; Leclerc JM; Rehel B
Can J Clin Pharmacol; 2008; 15(2):e177-87. PubMed ID: 18515919
[TBL] [Abstract][Full Text] [Related]
14. [Relation of serum levels of the soluble cytoadhesion molecules sVCAM-1 and sICAM-1 to selected factors in the cytokine network in multiple myeloma].
Scudla V; Budíková M; Bacovský J; Opíchalová D; Farbiaková V
Cas Lek Cesk; 2000 Jul; 139(13):401-6. PubMed ID: 10971970
[TBL] [Abstract][Full Text] [Related]
15. Hemodialysis procedure does not affect the levels of sICAM-1 and sVCAM-1 in patients with end stage renal disease.
Liakopoulos V; Eleftheriadis T; Kyropoulos T; Voliotis G; Potamianos S; Zengos N; Stefanidis I; Heintz B
Ren Fail; 2005; 27(3):315-21. PubMed ID: 15957549
[TBL] [Abstract][Full Text] [Related]
16. Sexual activity in hypertensive men.
Della Chiesa A; Pfiffner D; Meier B; Hess OM
J Hum Hypertens; 2003 Aug; 17(8):515-21. PubMed ID: 12874608
[TBL] [Abstract][Full Text] [Related]
17. [Intensive blood pressure reduction in patients with increased cardiovascular risk with high-dose combination therapy of 160 mg valsartan plus 25 mg hydrochlorothiazide. Results of the MACHT II observational study].
Schühlen H; Abts M; Kastrati D
Herz; 2007 Aug; 32(5):419-25. PubMed ID: 17687532
[TBL] [Abstract][Full Text] [Related]
18. Valsartan, blood pressure reduction, and C-reactive protein: primary report of the Val-MARC trial.
Ridker PM; Danielson E; Rifai N; Glynn RJ;
Hypertension; 2006 Jul; 48(1):73-9. PubMed ID: 16714425
[TBL] [Abstract][Full Text] [Related]
19. Aliskiren and valsartan in stage 2 hypertension: subgroup analysis of a randomized, double-blind study.
Yarows SA; Oparil S; Patel S; Fang H; Zhang J
Adv Ther; 2008 Dec; 25(12):1288-302. PubMed ID: 19066757
[TBL] [Abstract][Full Text] [Related]
20. Reduction of QTc dispersion by the angiotensin II receptor blocker valsartan may be related to its anti-oxidative stress effect in patients with essential hypertension.
Miyajima K; Minatoguchi S; Ito Y; Hukunishi M; Matsuno Y; Kakami M; Kawasaki M; Nishigaki K; Takemura G; Fujiwara H
Hypertens Res; 2007 Apr; 30(4):307-13. PubMed ID: 17541209
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
